The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of neural transmission

• Publication date

  2012-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00702-012-0815-xPMID 22569849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease

  2012cited by this paper
• Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.

  2011cited by this paper
• Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

  2011cited by this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cited by this paper
• Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter

  2010cited by this paper
• Boehringer Ingelheim withdraws libido drug for women

  2010cited by this paper
• Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women

  2010cited by this paper
• Decreased RGS9 protein level in the striatum of rodents undergoing MPTP or 6-OHDA neurotoxicity.

  2010cited by this paper
• Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson’s disease: a behavioral and neurochemical study in reserpinized mice

  2010cited by this paper
• Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.

  2009cited by this paper
• Analysis of genetic variations in the RGS9 gene and antipsychotic‐induced tardive dyskinesia in schizophrenia

  2009cited by this paper
• Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

  2009cited by this paper
• Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia

  2009cited by this paper
• Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats

  2009cited by this paper
• α1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques

  2009cited by this paper
• Dopamine receptors and L-dopa-induced dyskinesia.

  2009cited by this paper
• Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure

  2008cited by this paper
• Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.

  2008cited by this paper
• Motor coordination deficits in mice lacking RGS9.

  2008cited by this paper
• Levodopa-induced dyskinesias and their management

  2008cited by this paper
• Invited Article: Nervous system pathology in sporadic Parkinson disease

  2008cited by this paper
• The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

  2007cited by this paper
• Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.

  2007cited by this paper
• RGS9–2 Negatively Modulates l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease

  2007cited by this paper
• Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatment

  2007cited by this paper
• Pharmacology of flibanserin.

  2006cited by this paper
• Effects of baclofen on reserpine-induced vacuous chewing movements in mice.

  2006cited by this paper
• The partial dopamine D2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen

  2006cited by this paper
• Psychosis pathways converge via D2High dopamine receptors

  2006cited by this paper
• Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.

  2006cited by this paper
• A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.

  2005cited by this paper
• Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.

  2005cited by this paper
• Effects of sarizotan on the corticostriatal glutamate pathways

  2005cited by this paper
• Dopamine Modulation of State-Dependent Endocannabinoid Release and Long-Term Depression in the Striatum

  2005cited by this paper
• D2 Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways

  2005cited by this paper
• Nondopaminergic mechanisms in levodopa‐induced dyskinesia

  2005cited by this paper
• Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations

  2005cited by this paper
• Buspirone Raises Blood Pressure through Activation of Sympathetic Nervous System and by Direct Activation of α1-Adrenergic Receptors after Severe Hemorrhage

  2004cited by this paper
• 5-HT1 receptors.

  2004cited by this paper
• RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons.

  2004cited by this paper
• Buspirone raises blood pressure through activation of sympathetic nervous system and by direct activation of alpha1-adrenergic receptors after severe hemorrhage.

  2004cited by this paper
• Essential role for RGS9 in opiate action

  2003cited by this paper
• RGS9 modulates dopamine signaling in the basal ganglia.

  2003cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003cited by this paper
• Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum.

  2001cited by this paper
• PAST: PALEONTOLOGICAL STATISTICAL SOFTWARE PACKAGE FOR EDUCATION AND DATA ANALYSIS

  2001cited by this paper
• Slowed recovery of rod photoresponse in mice lacking the GTPase accelerating protein RGS9-1

  2000cited by this paper
• Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety

  2000cited by this paper
• Cloning and Characterization of RGS9-2: A Striatal-Enriched Alternatively Spliced Product of the RGS9 Gene

  1999cited by this paper
• A review of central 5-HT receptors and their function.

  1999cited by this paper
• Behavioral effects of flibanserin (BIMT 17).

  1999cited by this paper
• Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.

  1999cited by this paper
• G protein-coupled receptors: functional and mechanistic insights through altered gene expression.

  1998cited by this paper
• Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.

  1997cited by this paper
• Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant.

  1997cited by this paper
• Buspirone in levodopa-induced dyskinesias.

  1994cited by this paper
• Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression.

  1994cited by this paper
• Buspirone in the treatment of levodopa induced dyskinesias.

  1991cited by this paper
• Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.

  1977cited by this paper

• Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

  2022cites this paper
• Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-Antagonist

  2016cites this paper
• Mutual influence of serotonin and dopamine on the functioning of the dorsal striatum and motor activity (hypothetical mechanism)

  2014cites this paper
• Motor complications in Parkinson's disease: a comprehensive review of emergent management strategies.

  2013cites this paper